Literature DB >> 15126503

Interaction between glucose-regulated destruction domain of DNA topoisomerase IIalpha and MPN domain of Jab1/CSN5.

Jisoo Yun1, Akihiro Tomida, Toshiwo Andoh, Takashi Tsuruo.   

Abstract

DNA topoisomerase (topo) IIalpha, an essential enzyme for cell proliferation, is targeted to a proteasome-dependent degradation pathway when human tumor cells are glucose-starved. Here we show that the topo IIalpha destabilization depends on the newly identified domain, GRDD (glucose-regulated destruction domain), which was mapped to the N-terminal 70-170 amino acid sequence. Indeed, the deletion of GRDD conferred a stable feature on topo IIalpha, whereas the fusion of GRDD rendered green fluorescent protein unstable under glucose starvation conditions. Nuclear localization was a prerequisite for GRDD function, because the inhibition of nuclear translocation resulted in the suppression of GRDD-mediated topo IIalpha degradation. Further, GRDD was identified as an interactive domain for Jab1/CSN5, which promoted the degradation of topo IIalpha in a manner dependent on the MPN (Mpr1p/Prd1p N terminus) domain. Depleting Jab1/CSN5 by antisense oligonucleotide and treating cells with the CSN-associated kinase inhibitor, curcumin, inhibited topo IIalpha degradation induced by glucose starvation. These findings demonstrate that GRDD can act as a stress-activated degron for regulating topo IIalpha stability, possibly through interaction with the MPN domain of Jab1/CSN5.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15126503     DOI: 10.1074/jbc.M401411200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

Review 1.  DNA topoisomerase II and its growing repertoire of biological functions.

Authors:  John L Nitiss
Journal:  Nat Rev Cancer       Date:  2009-04-20       Impact factor: 60.716

Review 2.  The unfolded protein response and cancer: a brighter future unfolding?

Authors:  Peter Scriven; Nicola J Brown; A Graham Pockley; Lynda Wyld
Journal:  J Mol Med (Berl)       Date:  2007-01-10       Impact factor: 4.599

3.  Novel mechanism by which histone deacetylase inhibitors facilitate topoisomerase IIα degradation in hepatocellular carcinoma cells.

Authors:  Mei-Chuan Chen; Chun-Han Chen; Hsiao-Ching Chuang; Samuel K Kulp; Che-Ming Teng; Ching-Shih Chen
Journal:  Hepatology       Date:  2011-01       Impact factor: 17.425

Review 4.  The emerging role of the COP9 signalosome in cancer.

Authors:  Katharine S Richardson; Wayne Zundel
Journal:  Mol Cancer Res       Date:  2005-12       Impact factor: 5.852

5.  JAB1/CSN5 inhibits the activity of Luman/CREB3 by promoting its degradation.

Authors:  Lisa M DenBoer; Aarti Iyer; Adam R R McCluggage; Yu Li; Amanda C Martyn; Ray Lu
Journal:  Biochim Biophys Acta       Date:  2013-04-11

6.  JAB1/CSN5: a new player in cell cycle control and cancer.

Authors:  Terry J Shackleford; Francois X Claret
Journal:  Cell Div       Date:  2010-10-18       Impact factor: 5.130

7.  UPR-induced resistance to etoposide is downstream of PERK and independent of changes in topoisomerase IIα levels.

Authors:  Melissa J Mann; Ethel R Pereira; Nan Liao; Linda M Hendershot
Journal:  PLoS One       Date:  2012-10-29       Impact factor: 3.240

8.  Developmental expression of p97/VCP (Valosin-containing protein) and Jab1/CSN5 in the rat testis and epididymis.

Authors:  Sevil Cayli; Seda Ocakli; Fikret Erdemir; Ufuk Tas; Huseyin Aslan; Tamer Yener; Zafer Karaca
Journal:  Reprod Biol Endocrinol       Date:  2011-08-19       Impact factor: 5.211

9.  Low intensity focused ultrasound (LOFU) modulates unfolded protein response and sensitizes prostate cancer to 17AAG.

Authors:  Subhrajit Saha; Payel Bhanja; Ari Partanen; Wei Zhang; Laibin Liu; Wolfgang Tomé; Chandan Guha
Journal:  Oncoscience       Date:  2014-06-03

10.  The E3 ubiquitin-ligase Bmi1/Ring1A controls the proteasomal degradation of Top2alpha cleavage complex - a potentially new drug target.

Authors:  Iris Alchanati; Carmit Teicher; Galit Cohen; Vivian Shemesh; Haim M Barr; Philippe Nakache; Danny Ben-Avraham; Anna Idelevich; Itzchak Angel; Nurit Livnah; Shmuel Tuvia; Yuval Reiss; Daniel Taglicht; Omri Erez
Journal:  PLoS One       Date:  2009-12-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.